Int J Mol Sci. 2017 Aug 10;18(8). pii: E1739. doi: 10.3390/ijms18081739.
Abstract
We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 × 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated. Thus, cannabis-based medicine appears to be effective in treatment-resistant TS patients with vocal blocking tics.
KEYWORDS:
Tourette syndrome; blocking tics; cannabis; dysfluency; nabiximols; tics
- PMID: 28796166
- DOI: 10.3390/ijms18081739
-
Conflict of interest statement
The authors declare no conflict of interest.